AU2022407330A1 - Combination therapy comprising a pkc inhibitor and a c-met inhibitor - Google Patents

Combination therapy comprising a pkc inhibitor and a c-met inhibitor Download PDF

Info

Publication number
AU2022407330A1
AU2022407330A1 AU2022407330A AU2022407330A AU2022407330A1 AU 2022407330 A1 AU2022407330 A1 AU 2022407330A1 AU 2022407330 A AU2022407330 A AU 2022407330A AU 2022407330 A AU2022407330 A AU 2022407330A AU 2022407330 A1 AU2022407330 A1 AU 2022407330A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022407330A
Other languages
English (en)
Inventor
Jaymes Holland
Sarah Shwu-Kuan JAW-TSAI
Mai Hope LE
Matthew Anthony MAURER
Michael Gabriel O'QUIGLEY
Richard Zang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Ideaya Biosciences Inc
Original Assignee
PFIZER
Pfizer Inc
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc, Ideaya Biosciences Inc filed Critical PFIZER
Publication of AU2022407330A1 publication Critical patent/AU2022407330A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022407330A 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor Pending AU2022407330A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163286345P 2021-12-06 2021-12-06
US63/286,345 2021-12-06
US202263317573P 2022-03-08 2022-03-08
US63/317,573 2022-03-08
US202263370056P 2022-08-01 2022-08-01
US63/370,056 2022-08-01
PCT/US2022/080928 WO2023107894A1 (en) 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Publications (1)

Publication Number Publication Date
AU2022407330A1 true AU2022407330A1 (en) 2024-07-04

Family

ID=86731264

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022407330A Pending AU2022407330A1 (en) 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Country Status (8)

Country Link
US (1) US20240335440A1 (https=)
EP (1) EP4444303A4 (https=)
JP (1) JP2024542831A (https=)
AU (1) AU2022407330A1 (https=)
CA (1) CA3239676A1 (https=)
IL (1) IL313361A (https=)
MX (1) MX2024006948A (https=)
WO (1) WO2023107894A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174478A1 (en) * 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US11413284B2 (en) * 2017-09-12 2022-08-16 Novartis Ag Protein kinase C inhibitors for treatment of uveal melanoma
AU2020386903A1 (en) * 2019-11-18 2022-06-09 Ideaya Biosciences, Inc. Dosing regimens for a protein kinase C inhibitor
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療

Also Published As

Publication number Publication date
CA3239676A1 (en) 2023-06-15
EP4444303A4 (en) 2025-11-26
EP4444303A1 (en) 2024-10-16
US20240335440A1 (en) 2024-10-10
WO2023107894A1 (en) 2023-06-15
JP2024542831A (ja) 2024-11-15
IL313361A (en) 2024-08-01
MX2024006948A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
EP3574904B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2025111571A (ja) 消化管間質腫瘍の治療のための併用療法
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US20240207257A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
US20250090514A1 (en) Method of treating cancer
TW202332431A (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
CN115038447A (zh) 用于治疗癌症的组合疗法
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
WO2023175477A1 (en) Treatment of breast cancer with amcenestrant
AU2024259627A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
EP4085908A1 (en) Pharmaceutical combination for treating tumors and application thereof
KR20240148328A (ko) 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK40116103A (zh) 尼拉帕尼和醋酸阿比特龙加泼尼松用於改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos